Drug Profile


Alternative Names: 23F2G; Hu23F2G; LeukArrest

Latest Information Update: 17 May 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ICOS Corporation
  • Class Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Cerebral vasospasm; CNS trauma; Multiple sclerosis; Myocardial infarction; Peripheral arterial occlusive disorders; Shock; Stroke; Vascular restenosis

Most Recent Events

  • 17 May 2002 Discontinued - Preclinical for Cerebral vasospasm in USA (unspecified route)
  • 17 May 2002 Discontinued - Preclinical for CNS trauma in USA (unspecified route)
  • 17 May 2002 Discontinued - Preclinical for Peripheral arterial occlusive disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top